ProPhase Labs 

$0.020000
65
+$0.00+17.65% Friday 19:43
-$0.00-13.5%Friday 20:00After hours

Statistics

Day High
0.02
Day Low
0.017
52W High
6.7
52W Low
0.017
Volume
42,314
Avg. Volume
155,357
Mkt Cap
280,320
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 22
$3.00
Mar 22
$3.00
Jun 21
$3.00
Dec 19
$2.50
Jan 19
$2.50
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.86
-1.28
-0.69
-0.11
Expected EPS
N/A
Actual EPS
N/A

Financials

-339.31%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.35MRevenue
-14.74MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRPH. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson is a major competitor in the healthcare sector, offering a wide range of products that could compete with ProPhase Labs' offerings in diagnostics and health services.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories competes with ProPhase Labs in the diagnostics and medical devices sector, particularly in the development of tests and health monitoring devices.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical and biotechnology corporation that competes with ProPhase Labs in the research, development, and marketing of healthcare products.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that competes with ProPhase Labs in the pharmaceuticals and health services market, including the development of treatments and diagnostics.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company that competes with ProPhase Labs in the development and marketing of prescription medicines across several therapeutic areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is a biopharmaceutical company that competes with ProPhase Labs in the development and marketing of antiviral drugs used in the treatment of infectious diseases.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is a biopharmaceutical company that competes with ProPhase Labs in the discovery, development, and delivery of innovative human therapeutics.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. competes with ProPhase Labs in the biopharmaceutical field, focusing on developing and marketing advanced therapies for complex and serious diseases.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a global pioneer in pharmaceuticals and diagnostics that competes with ProPhase Labs in the diagnostics and personalized healthcare sectors.
Novartis
NVS
Mkt Cap292.35B
Novartis AG is a global healthcare company that competes with ProPhase Labs in developing and marketing a wide range of healthcare products, including innovative medicines and diagnostics.

About

ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Show more...
CEO
Ted William Karkus
Employees
19
Country
United States
ISIN
US74345W2070

Listings

0 Comments

Share your thoughts

FAQ

What is ProPhase Labs stock price today?
The current price of PRPH is $0.02 USD — it has increased by +17.65% in the past 24 hours. Watch ProPhase Labs stock price performance more closely on the chart.
What is ProPhase Labs stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange ProPhase Labs stocks are traded under the ticker PRPH.
Is ProPhase Labs stock price growing?
PRPH stock has fallen by -9.5% compared to the previous week, the month change is a -54.75% fall, over the last year ProPhase Labs has showed a -99.44% decrease.
What is ProPhase Labs market cap?
Today ProPhase Labs has the market capitalization of 280,320
When is the next ProPhase Labs earnings date?
ProPhase Labs is going to release the next earnings report on November 05, 2026.
What is ProPhase Labs revenue for the last year?
ProPhase Labs revenue for the last year amounts to 4.35M USD.
What is ProPhase Labs net income for the last year?
PRPH net income for the last year is -14.74M USD.
Does ProPhase Labs pay dividends?
Yes, PRPH dividends are paid annual. The last dividend per share was 3 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does ProPhase Labs have?
As of September 05, 2026, the company has 19 employees.
In which sector is ProPhase Labs located?
ProPhase Labs operates in the Health & Wellness sector.
When did ProPhase Labs complete a stock split?
The last stock split for ProPhase Labs was on December 22, 2025 with a ratio of 1:10.
Where is ProPhase Labs headquartered?
ProPhase Labs is headquartered in Uniondale, United States.